



Hsyueh-Liang Wu and Biing-Jiun Uang*

Tetrahedron: Asymmetry 13 (2002) 2625(1*S,4R*)-7,7-Dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbohydroxamic acid



E.e. >99%

 $[\alpha]_D^{23} +130.8$ (*c* 1.20, CHCl₃)

Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S,4R*

Hsyueh-Liang Wu and Biing-Jiun Uang*

Tetrahedron: Asymmetry 13 (2002) 2625(1*S,4R*)-*N*-Benzyl-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbohydroxamic acid



E.e. >99%

 $[\alpha]_D^{23} -82.6$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S,4R*

Hsyueh-Liang Wu and Biing-Jiun Uang*

Tetrahedron: Asymmetry 13 (2002) 2625(1*S,4R*)-*N*-Cyclohexyl-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbohydroxamic acid



E.e. >99%

 $[\alpha]_D^{23} -58.9$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S,4R*

Hsyueh-Liang Wu and Biing-Jiun Uang*



Tetrahedron: Asymmetry 13 (2002) 2625(1*S,4R*)-*N*-Benzhydryl-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -47.2$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid



Absolute configuration: 1*S,4R*

(1*S*,*4R*)-*N*-Adamantyl-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -43.0$ (*c* 1.0, CHCl₃)



Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S*,*4R*(1*S*,*4R*)-7,7-Dimethyl-2-phenylbicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -156.9$ (*c* 1.0, CHCl₃)



Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S*,*4R*(1*S*,*4R*)-7,7-Dimethyl-2-(4-methylphenyl)bicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -190.2$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid



Absolute configuration: 1*S*,*4R*(1*S*,*4R*)-7,7-Dimethyl-2-[4-(butyl)phenyl]bicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -177.6$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid



Absolute configuration: 1*S*,*4R*

(1*S*,*4R*)-7,7-Dimethyl-2-(1-naphthyl)bicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{22} -94.2$ (*c* 1.0, CHCl₃)



Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S*,4*R*(1*S*,*4R*)-7,7-Dimethyl-2-(4-biphenyl)bicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%

 $[\alpha]_D^{23} -111.2$ (*c* 1.62, CHCl₃)

Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S*,4*R*(1*S*,*4R*)-*N*-Benzhydryl-7,7-dimethyl-2-phenylbicyclo[2.2.1]heptane-1-carbohydroxamic acid

E.e. >99%


 $[\alpha]_D^{22} -106.0$ (*c* 1.0, CHCl₃)

Source of chirality: (+)-ketopinic acid

Absolute configuration: 1*S*,4*R*(1*S*)-7,7-Dimethyl-2-methylene-1-(methylsulfanyl)bicyclo[2.2.1]heptane $[\alpha]_D^{20} -32.1$ (*c* 5.58, CH₂Cl₂)Source of chirality: (1*R*)-fenchoneAbsolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₂H₂₀S
(1*S*)-1-(Ethylsulfanyl)-7,7-dimethyl-2-methylenecyclo[2.2.1]heptane


[α]_D²⁰ -22.3 (*c* 0.40, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₃H₂₂S
(1*S*)-1-(Isopropylsulfanyl)-7,7-dimethyl-2-methylenecyclo[2.2.1]heptane


[α]_D²⁰ -21.4 (*c* 1.99, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₄H₂₄S
(1*S*)-1-(tert-Butylsulfanyl)-7,7-dimethyl-2-methylenecyclo[2.2.1]heptane


[α]_D²⁰ +4.8 (*c* 1.43, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₄H₂₄S
(1*S*)-1-(Butylsulfanyl)-7,7-dimethyl-2-methylenecyclo[2.2.1]heptane


[α]_D²⁰ -25.2 (*c* 1.16, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₆H₂₀S

(1*S*)-7,7-Dimethyl-2-methylene-1-(phenylsulfanyl)bicyclo[2.2.1]heptane


[α]_D²⁰ +29.7 (*c* 3.20, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₁H₁₅NS

(1*S*)-7,7-Dimethyl-2-methylenebicyclo[2.2.1]hept-1-yl thiocyanate


[α]_D²⁰ -43.3 (*c* 1.59, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₁H₁₅NS

(1*R*)-3,3-dimethyl-2-methylenebicyclo[2.2.1]hept-1-yl thiocyanate


[α]_D²⁰ -45.6 (*c* 2.04, CH₂Cl₂)

Source of chirality: (1*R*)-camphor

Absolute configuration: 1*R*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



C₁₅H₂₀O₂S

Ethyl 3-[(1*S*)-7,7-dimethyl-2-methylenebicyclo[2.2.1]hept-1-yl]sulfanyl]-2-propynoate



[α]_D²⁰ -31.4 (*c* 2.39, CH₂Cl₂)

Source of chirality: (1*R*)-fenchone

Absolute configuration: 1*S*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



Ethyl 3-{[(1R)-3,3-dimethyl-2-methylenebicyclo[2.2.1]hept-1-yl]sulfanyl}-2-propynoate

[α]_D²⁰ -74.2 (*c* 1.46, CH₂Cl₂)

Source of chirality: (1*R*)-camphor

Absolute configuration: 1*R*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



(1*R*)-1-(Ethylsulfanyl)-3,3-dimethyl-2-methylenebicyclo[2.2.1]heptane

[α]_D²⁰ -54.6 (*c* 0.93, CH₂Cl₂)

Source of chirality: (1*R*)-camphor

Absolute configuration: 1*R*

Antonio García Martínez,* Enrique Teso Vilar,*
Florencio Moreno Jiménez, Ana María Álvarez García
and Patricia Pinilla Rodríguez

Tetrahedron: Asymmetry 13 (2002) 2635



(1*R*)-1-(Isopropylsulfanyl)-3,3-dimethyl-2-methylenebicyclo[2.2.1]heptane



[α]_D²⁰ -87.2 (*c* 2.10, CH₂Cl₂)

Source of chirality: (1*R*)-camphor

Absolute configuration: 1*R*

Yoshiki Morimoto,* Toshiyuki Iwai, Yoshihiro Nishikawa
and Takamasa Kinoshita

Tetrahedron: Asymmetry 13 (2002) 2641




(2*S*,3*S*,6*E*)-8-*tert*-Butyldimethylsilyloxy-2,7-dimethyl-2,3-epoxyoct-6-en-1-ol

Ee = 98%

[α]_D²⁴ = -9.80 (*c* 1.02, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*,3*S*)




(*2E,6S,7S*)-1-*tert*-Butyldimethylsilyloxy-8-methoxymethoxy-2,7-dimethyl-6,7-epoxyoct-2-ene

Ee = 98%

$[\alpha]_D^{25} = -5.25$ (*c* 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (6*S*,7*S*)




(*2E,6S,7S*)-8-Methoxymethoxy-2,7-dimethyl-6,7-epoxyoct-2-en-1-ol

Ee = 98%

$[\alpha]_D^{24} = -3.85$ (*c* 0.73, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (6*S*,7*S*)




(*2R,3R,6S,7S*)-8-Methoxymethoxy-2,7-dimethyl-2,3-epoxy-6,7-epoxyoctan-1-ol

$[\alpha]_D^{25} = -2.66$ (*c* 1.10, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*R*,3*R*,6*S*,7*S*)




(*2R,5R*)-2,5-Bis[(1*S*)-1,2-dihydroxy-1-methylethyl]tetrahydrofuran

$[\alpha]_D^{25} = +6.27$ (*c* 1.13, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*R*,5*R*)-[(1*S*)]




(2R,5R)-2,5-Bis[(1S)-1-methyl-1,2-epoxyethyl]tetrahydrofuran

[α]_D²⁵ = +9.75 (*c* 0.843, MeOH)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*R*,5*R*)-[(1*S*)]




3,4-*O*-Isopropylidene-L-arabinono-1,5-lactone

E.e. = 100%

[α]_D²¹ = -29.2 (*c* 1.01, CHCl₃)

Source of chirality: L-arabinose as starting material




3,4-*O*-Isopropylidene-2-*O*-trifluoromethanesulfonyl-L-arabinono-1,5-lactone

E.e. = 100%

[α]_D²⁰ = +24.5 (*c* 1.04, CHCl₃)

Source of chirality: L-arabinose as starting material




2-Deoxy-3,4-*O*-isopropylidene-L-ribono-1,5-lactone

E.e. = 100%

[α]_D²³ = +148.1 (*c* 1.03, CHCl₃)

Source of chirality: L-arabinose as starting material




C₁₁H₁₃NO₂
(R)-1-(3-Pyridyl)-but-3-en-1-yl acetate

Ee = 98%

[α]_D = +55.1 (*c* 1.40, CH₂Cl₂)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*

C₁₁H₁₃NO₂
(R)-1-(2-Pyridyl)-but-3-en-1-yl acetate

Ee = 99%

[α]_D = +78.7 (*c* 1.50, CH₂Cl₂)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*

C₁₁H₁₃NO₂
(R)-1-(4-Pyridyl)-but-3-en-1-yl acetate

Ee = 99%

[α]_D = +58.7 (*c* 1.30, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


C₁₂H₁₆N₂O₄
(R)-5-(1-Acetoxy-but-3-enyl)-1,3-dimethyl-1*H*-pyrimidine-2,4-dione

Ee = 98%

[α]_D = +66.5 (*c* 0.52, CH₂Cl₂)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


 $C_{12}H_{16}N_2O_4$

(R)-1-(2,4-Dimethoxy-pyrimidin-5-yl)-but-3-en-1-yl acetate

Ee = 95%

 $[\alpha]_D = +49.4$ (*c* 1.05, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_{15}H_{14}O_4$

(R)-3-(1-Acetoxy-but-3-enyl)-chromen-4-one

Ee = 97%

 $[\alpha]_D = +51.2$ (*c* 0.82, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_{10}H_{12}O_2S$

(R)-1-(2-Thienyl)-but-3-en-1-yl acetate

Ee = 98%

 $[\alpha]_D = +35.21$ (*c* 1.40, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R* $C_{10}H_{12}O_3$


(R)-1-(2-Furyl)-but-3-en-1-yl acetate

Ee = 96%

 $[\alpha]_D = +23.2$ (*c* 1.06, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


 $C_{11}H_{11}NO_2$

(R)-1-(3-Pyridyl)-but-3-yn-1-yl acetate

Ee = 98%

 $[\alpha]_D = +49.25$ (*c* 1.30, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_{11}H_{11}NO_2$

(R)-1-(3-Pyridyl)-buta-2,3-dien-1-yl acetate

Ee = 94%

 $[\alpha]_D = -63.9$ (*c* 0.81, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_9H_{11}NO$

(R)-1-(3-Pyridyl)-but-3-en-1-ol

Ee = 98%

 $[\alpha]_D = +48.4$ (*c* 0.90, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R* $C_9H_{11}NO$


(R)-1-(2-Pyridyl)-but-3-en-1-ol

Ee = 99%

 $[\alpha]_D = +47.1$ (*c* 1.20, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


 $C_9H_{11}NO$

(R)-1-(4-Pyridyl)-but-3-en-1-ol

Ee = 99%

 $[\alpha]_D = +70.0$ (*c* 0.95, CH_2Cl_2)


Source of chirality: enzymatic resolution

Absolute configuration: 1*R* $C_{10}H_{14}N_2O_3$ (R)-5-(1-Hydroxy-but-3-enyl)-1,3-dimethyl-1*H*-pyrimidine-2,4-dione

Ee = 98%

 $[\alpha]_D = +55.4$ (*c* 0.37, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_{10}H_{14}N_2O_3$

(R)-1-(2,4-Dimethoxy-pyrimidin-5-yl)-but-3-en-1-ol

Ee = 91%

 $[\alpha]_D = +60.5$ (*c* 0.92, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R* $C_{13}H_{12}O_3$


(R)-3-(1-Hydroxy-but-3-en-1-yl)-chromen-4-one

Ee = 97%

 $[\alpha]_D = +54.1$ (*c* 0.61, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


 $C_8H_{10}OS$

(R)-1-(2-Thienyl)-but-3-en-1-ol

Ee = 98%

 $[\alpha]_D = +10.1$ (*c* 0.80, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* $C_8H_{10}O_2$

(R)-1-(2-Furyl)-but-3-en-1-ol

Ee = 96%

 $[\alpha]_D = +37.2$ (*c* 0.90, CH_2Cl_2)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R* C_9H_9NO

(R)-1-(3-Pyridyl)-but-3-yn-1-ol

Ee = 98%

 $[\alpha]_D = +48.3$ (*c* 0.35, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R* C_9H_9NO


(R)-1-(3-Pyridyl)-buta-2,3-dien-1-ol

Ee = 94%

 $[\alpha]_D = -71.4$ (*c* 0.64, CH_2Cl_2)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*


 $C_{20}H_{24}O_7$

(S,S)-2,2'-Dimethoxy-4-(3-hydroxy-1-propenyl)-4'-(1,2,3-trihydroxypropyl) diphenyl ether

E.e. = 92%

 $[\alpha]_D^{25} = +0.7$ (*c* 1.0, MeOH)

Source of chirality: Sharpless asymmetric dihydroxy reaction


Absolute configuration: *S,S* $C_{20}H_{24}O_7$

(R,R)-2,2'-Dimethoxy-4-(3-hydroxy-1-propenyl)-4'-(1,2,3-trihydroxypropyl) diphenyl ether

E.e. = 92%

 $[\alpha]_D^{25} = -1.4$ (*c* 1.0, MeOH)

Source of chirality: Sharpless asymmetric dihydroxy reaction


Absolute configuration: *R,R* $C_{33}H_{29}NO_3$

(S)-Acetic acid 2-(quinolin-4-yl)-3-(trytyloxy)propyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +31.4$ (*c* 2.06, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S* $C_{34}H_{31}NO_4$


(S)-Acetic acid 3-{[(p-methoxyphenyl)diphenyl]methoxy}-2-(quinolin-4-yl)propyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +30.4$ (*c* 1.08, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S*

 $C_{35}H_{33}NO_5$ (S)-Acetic acid 3-{[bis-(*p*-methoxyphenyl)phenyl]methoxy}-2-(quinolin-4-yl)propyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +33.0$ (*c* 1.31, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S* $C_{31}H_{27}NO_2$

(R)-2-(Quinolin-4-yl)-3-(trityloxy)propan-1-ol

E.e. = 98%

 $[\alpha]_D^{25} = +59.7$ (*c* 2.18, CHCl₃)

Source of chirality: enzymatic asymmetrication


Absolute configuration: *R* $C_{37}H_{41}NO_2Si$

(S)-4-{1-[(Triethylsilyl)oxymethyl]-2-(trityloxy)ethyl}quinoline

E.e. = 98%

 $[\alpha]_D^{25} = +15.6$ (*c* 2.06, CHCl₃)

Source of chirality: enzymatic asymmetrication


Absolute configuration: *S* $C_{38}H_{33}NO_3$ (S)-4-[1-(*p*-Methoxyphenoxy)methyl]-2-(trityloxy)ethyl]quinoline

E.e. = 98%

 $[\alpha]_D^{25} = -13.0$ (*c* 2.00, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: *S*

 $C_{45}H_{43}NO_5Si$


(4'-(S)-[1-(Acetoxy)methyl-2-trityloxyethyl]-2-{(R)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +115.1$ (*c* 1.08, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: 4'S,2R

 $C_{45}H_{43}NO_5Si$


(4'S)-4-{[1-(Acetoxy)methyl-2-trityloxyethyl]-2-{(S)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = -83.1$ (*c* 0.79, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: 4'S,2S

 $C_{46}H_{45}NO_6Si$


(4'S)-4-{[1-(Acetoxy)methyl-2-(p-methoxyphenyl)diphenylmethoxyethyl]-2-{(R)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +207.9$ (*c* 1.46, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: 4'S,2R

 $C_{46}H_{45}NO_6Si$


(4'S)-4-{[1-(Acetoxy)methyl-2-(p-methoxyphenyl)diphenylmethoxyethyl]-2-{(S)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = -179.3$ (*c* 0.44, CHCl₃)

Source of chirality: enzymatic asymmetrication

Absolute configuration: 4'S,2S




(4'R)-4-{{[1-Hydroxymethyl-2-trityloxy]ethyl}-2-[(R)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = +255.00$ (*c* 1.75, CHCl₃)

Source of chirality: enzymatic asymmetrication


Absolute configuration: 4'R,2*R*

(4'R)-4-{{[1-Hydroxymethyl-2-trityloxy]ethyl}-2-[(S)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = -227.8$ (*c* 1.16, CHCl₃)

Source of chirality: enzymatic asymmetrication


Absolute configuration: 4'R,2*S*

(4'S)-4-{{[1-(Toluene-4-sulfonyloxy)methyl]-2-trityloxy}ethyl}-2-[(S)-[(trimethylsilyl)ethynyl]}-2H-quinoline-1-carboxylic acid phenyl ester

E.e. = 98%

 $[\alpha]_D^{25} = -60.5$ (*c* 1.32, CHCl₃)

Source of chirality: enzymatic asymmetrication


Absolute configuration: 4'S,2*S*

(2S,3S,4aR,8aR)-2,3-Bis(4-fluorophenyl)-decahydroquinoxaline

E.e. = 100%

 $[\alpha]_D^{20} = -61.0$ (*c* 0.384, CH₂Cl₂)

Source of chirality: (R,R)-1,2-diaminocyclohexane




C₂₂H₂₈N₂O₂

(2S,3S,4aR,8aR)-2,3-Bis(4-methoxyphenyl)-decahydroquinoxaline

E.e. = 100%

[α]_D²⁰ = -114.7 (c 0.204, CH₂Cl₂)

Source of chirality: (R,R)-1,2-diaminocyclohexane




C₂₀H₂₄N₂O₂

(2S,3S,4aR,8aR)-2,3-Bis(2-hydroxyphenyl)-decahydroquinoxaline

E.e. = 100%

[α]_D²⁰ = -20.5 (c 1.186, CH₂Cl₂)

Source of chirality: (R,R)-1,2-diaminocyclohexane




C₂₆H₃₂N₂

(2S,3S,4aR,8aR)-2,3-Diphenyl-1,4-diallyl-decahydroquinoxaline

E.e. = 100%

[α]_D²⁰ = -73.8 (c 0.336, CH₂Cl₂)

Source of chirality: (R,R)-1,2-diaminocyclohexane




C₃₄H₃₂N₂O₂

(2S,3S,4aR,8aR)-2,3-Diphenyl-1,4-dibenzoyl-decahydroquinoxaline

E.e. = 100%

[α]_D²⁰ = +43.0 (c 0.360, CH₂Cl₂)

Source of chirality: (R,R)-1,2-diaminocyclohexane




(*2S,3S,4aR,8aR*)-2,3-Diphenyl-1,4-dibenzyl-decahydroquinoxaline

E.e. = 100%

$[\alpha]_D^{20} = -156.0$ (*c* 0.442, CH₂Cl₂)

Source of chirality: (*R,R*)-1,2-diaminocyclohexane



C₂₈H₂₆N₂O₂

5,12-{{[(1*S*,2*S*)-1,2-Diphenyl]etheno}-(4*aR*,12*aR*)-1,2,3,4,4*a*,6,11,12*a*-octahydrodibenzo[*b,f*]1,4-diazocene-6,11-dione

E.e. = 100%

$[\alpha]_D^{20} = +248.0$ (*c* 0.364, CH₂Cl₂)

Source of chirality: (*R,R*)-1,2-diaminocyclohexane